BIOBOSTON CONSULTINGโ€™s Post

View organization page for BIOBOSTON CONSULTING, graphic

2,921 followers

๐—™๐——๐—” ๐—”๐—ฝ๐—ฝ๐—ฟ๐—ผ๐˜ƒ๐—ฒ๐˜€ ๐—˜๐—น๐—ถ ๐—Ÿ๐—ถ๐—น๐—น๐˜†โ€™๐˜€ ๐——๐—ผ๐—ป๐—ฎ๐—ป๐—ฒ๐—บ๐—ฏ ๐˜๐—ผ ๐—ง๐—ฟ๐—ฒ๐—ฎ๐˜ ๐—”๐—น๐˜‡๐—ต๐—ฒ๐—ถ๐—บ๐—ฒ๐—ฟโ€™๐˜€ ๐——๐—ถ๐˜€๐—ฒ๐—ฎ๐˜€๐—ฒ ๐—ง๐—ฎ๐—น๐—ธ ๐˜„๐—ถ๐˜๐—ต ๐—ฎ๐—ป ๐—ฒ๐˜…๐—ฝ๐—ฒ๐—ฟ๐˜ ๐Ÿ‘‰https://lnkd.in/e52sdG3P ๐Ÿ”น The FDA has approved Eli Lilly's donanemab, an anti-amyloid antibody marketed as Kisunla, making it the third drug approved to modify the course of Alzheimerโ€™s disease. This approval follows the previously approved anti-amyloid antibodies, Biogen and Eisaiโ€™s Aduhelm, and Leqembi, which has been commercially successful. The FDA's decision, supported by a favorable advisory committee vote, underscores the positive stance on donanemab despite concerns over trial design and safety, particularly amyloid-related imaging abnormalities (ARIA). ๐Ÿ”นExperts anticipate that donanemabโ€™s approval will benefit the broader market, including Leqembi, by enhancing diagnostic and treatment options for Alzheimerโ€™s disease. Contact BIOBOSTON CONSULTING today or visit our website at https://lnkd.in/dfarwCK2 to learn more about how we can support your organization. #compliance #quality #regulatory #clinical #pharmaceutical #biotechnology #consulting #fda

Quality Assurance & Regulatory Compliance | BioBoston Consulting

Quality Assurance & Regulatory Compliance | BioBoston Consulting

biobostonconsulting.com

To view or add a comment, sign in

Explore topics